News & Analysis as of

Financial Institutions Pfizer

Robins Kaplan LLP

Peloton Reels from Big Quarterly Losses

Robins Kaplan LLP on

Peloton’s quarterly earnings report showed that the company’s early-pandemic boom times are now firmly behind it, as the connected fitness bike maker delivered losses of $757 million for the first three months of 2022—“far...more

Robins Kaplan LLP

Financial Daily Dose 11.16.2020 | Top Story: PNC Financial Reaches $11.6B Deal to Buy BBVA American Operations

Robins Kaplan LLP on

Pittsburgh-based PNC Financial Services Group has reached a deal worth some $11.6 billion to buy the U.S. operations of BBVA, a Spanish lender. The mash-up, “one of the biggest banking deals since the 2008 financial crisis,”...more

Cadwalader, Wickersham & Taft LLP

2016 Year In Review: Securities Litigation And Regulation

2016 was an active year in securities litigation. In the first half of 2016 alone, plaintiffs filed 119 new federal class action securities cases. It was also a busy year for SEC enforcement proceedings, with a record 868...more

Robins Kaplan LLP

Your daily dose of financial news - The Brief – 8.23.16

Robins Kaplan LLP on

The 2d Circuit has refused the DOJ’s motion for reconsideration of the panel’s May decision overturning a jury verdict and accompanying $1.27 billion fine against Bank of America over its “Hustle” mortgage generation program....more

Robins Kaplan LLP

Your daily dose of financial news - The Brief – 8.22.16

Robins Kaplan LLP on

The SEC’s opened an inquiry into Hampton Creek in response to a Bloomberg report that the Just Mayo maker used undercover contractors to purchase its non-egg mayonnaise product in bulk not long before HC raised $90 million...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 5.17.16

Robins Kaplan LLP on

Gannet’s still after Tribune Publishing, and it’s upped its ante after Tribune “resoundingly rejected” early overtures – NYTimes... The Journal walks us through the fall of the Laplanche empire at Lending Club with a...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 5.11.16

Robins Kaplan LLP on

The fallout from Lending Club’s surprise news about Renaud Laplanche’s departure continues, with Goldman Sachs and Jeffries LLC hitting the pause on planned LC bond sales – WSJ... A Treasury Department white paper...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 4.8.16

Robins Kaplan LLP on

The Deal Professor looks back on a wild week of “deal busting” that saw the government [often in the form of Treasury Secretary Jack Lew] put the hurt on Pfizer/Allergan and Halliburton/Baker Hughes alike – NYTimes... ...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 4.7.16

Robins Kaplan LLP on

The DOJ has moved to block the proposed Halliburton/Baker Hughes merger in a Delaware-based federal lawsuit that argues that “combining the two oil field services companies would cut competition in the industry to...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 4.6.16

Robins Kaplan LLP on

Talk about a regulation with teeth. Within days of the Treasury Department announcing new rules meant to discourage corporate tax inversion deals, Pfizer and Allergan announced they were scrapping their planned $152 billion...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 4.5.16

Robins Kaplan LLP on

Big news from Big Mouse, as the former heir apparent to Bog Iger’s CEO chair—Thomas Staggs—is stepping down, throwing a wrench into Disney’s succession plans (which came under great scrutiny after a troublesome handoff to...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 11.25.15

Robins Kaplan LLP on

A groundbreaking move by Calpers—California’s state pension fund—to disclose how much money it’s made from and paid to private equity funds ($24.2 billion and $3.4 billion, respectively, since 1990) may help pave the way for...more

Robins Kaplan LLP

Your daily dose of financial news The Brief – 11.24.15

Robins Kaplan LLP on

The Pfizer/Allergan deal continues to dominate the financial world, with Pfizer’s CEO defending the merger and Washington searching for ways to reform the corporate tax code and prevent future tax-motivated corporate...more

13 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide